시장보고서
상품코드
1975333

당뇨병 관련 안과 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

Global Diabetes Associated Ophthalmic Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034

발행일: | 리서치사: 구분자 Value Market Research | 페이지 정보: 영문 153 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

당뇨병 관련 안과 치료 시장 규모는 2025년 408억 2,000만 달러에서 2026년부터 2034년까지 CAGR 7.16%로 성장하여 2034년에는 760억 6,000만 달러에 달할 것으로 예측됩니다.

세계 당뇨병 관련 안과 치료 시장은 당뇨병 유병률 증가 및 당뇨망막병증, 황반부종 등 안과 합병증 증가에 따라 확대되고 있습니다. 스크리닝 프로그램의 확대, 진단 영상 기술의 향상, 의료진의 인식 개선으로 환자 식별 및 치료 시작이 촉진되고 있습니다. 또한, 기존 치료법보다 시력 손실에 효과적으로 대처하는 항VEGF 요법, 지속 방출형 임플란트, 병용요법 등의 혁신도 시장 성장을 뒷받침하고 있습니다.

주요 성장 요인으로는 인구통계학적 변화(고령화), 전 세계 제2형 당뇨병 증가, 개발도상국의 안과 의료 접근성 확대, 망막 영상 진단 기술 및 약물전달 기술의 발전 등을 꼽을 수 있습니다. 또한, 보험 환급 제도 개선과 조기 발견 및 조기 개입을 촉진하는 공중보건 정책도 치료 도입을 촉진하고 있습니다. 또한, 장기지속형 약제 및 최소침습적 투여법에 대한 임상연구의 발전으로 치료 지속율 향상과 반복 치료의 촉진도 기대됩니다.

세계 당뇨병 관련 안과 치료 시장의 향후 전망은 보다 개인화된 치료 계획, 더 오래 지속되는 치료약물, 검진 및 경과 관찰에 있어 원격 안과 진료의 활용 확대 등이 제시되고 있습니다. 새로운 경로를 타겟으로 한 파이프라인의 혁신, 유전자 치료, 지속형 디바이스는 치료 패러다임을 재구성하고 진료 부담을 줄일 수 있습니다. 의료 시스템이 당뇨병 환자의 시력 유지를 우선시하는 가운데, 지속적인 효과, 우수한 안전성 프로파일, 비용 효율성을 입증하는 기업이 시장 확대를 주도할 가능성이 높습니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 당뇨병 관련 안과 치료 시장 : 용도별

제5장 세계의 당뇨병 관련 안과 치료 시장 : 유형별

제6장 세계의 당뇨병 관련 안과 치료 시장 : 최종사용별

제7장 세계의 당뇨병 관련 안과 치료 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

KSM 26.04.03

The Diabetes Associated Ophthalmic Treatment Market size is expected to reach USD 76.06 Billion in 2034 from USD 40.82 Billion (2025) growing at a CAGR of 7.16% during 2026-2034.

The Global Diabetes Associated Ophthalmic Treatment Market has expanded alongside the rising prevalence of diabetes and its ocular complications such as diabetic retinopathy and macular edema. Increasing screening programs, improved diagnostic imaging, and greater clinician awareness have driven patient identification and treatment initiation. The market's growth is also supported by innovations in anti-VEGF therapies, sustained-release implants, and combination regimens that address vision loss more effectively than past options.

Critical drivers include demographic shifts (aging populations), the global rise in type 2 diabetes, expanding access to ophthalmic care in developing regions, and technological advances in retinal imaging and drug delivery. Reimbursement improvements and public health initiatives promoting early detection and intervention also stimulate treatment uptake. Additionally, clinical research into longer-acting agents and less invasive administration methods encourages broader adherence and repeat treatments.

Future prospects for the Global Diabetes Associated Ophthalmic Treatment Market point to more personalized regimens, longer-duration therapeutics, and greater use of tele-ophthalmology for screening and follow-up. Pipeline innovations targeting novel pathways, gene therapies, and sustained-release devices could reshape treatment paradigms and lower clinic burden. Companies that demonstrate durable efficacy, favorable safety profiles, and cost-effectiveness are likely to lead market expansion as healthcare systems prioritize vision preservation in diabetic populations.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

  • Dry Eye Syndrome
  • Glaucoma
  • Eye Allergy & Infection
  • Diabetic Retinopathy
  • Diabetic Associated Macular Degeneration
  • Uveitis
  • Cataract
  • Diabetic Macular Edema
  • Others

By Type

  • Drugs
  • Devices

By End Use

  • Hospitals
  • Ophthalmic Centres
  • Ambulatory Centres
  • Others

COMPANIES PROFILED

  • Alcon, Johnson Johnson Services Inc, Bausch Health Companies Inc, F HoffmannLa Roche Ltd, Santen Pharmaceutical Co Ltd, Novartis AG, Pfizer Inc, Genentech Inc, Carl Zeiss Meditec, Lumenis, Ellex Medical Lasers Ltd, IRIDEX Corp, Topcon Corp, Abbott Medical Optics, Quantel
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Application
  • 4.2. Dry Eye Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Eye Allergy & Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Diabetic Retinopathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Diabetic Associated Macular Degeneration Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Uveitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Cataract Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.9. Diabetic Macular Edema Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: BY END USE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End Use
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Ophthalmic Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Ambulatory Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Application
    • 7.2.2 By Type
    • 7.2.3 By End Use
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Application
    • 7.3.2 By Type
    • 7.3.3 By End Use
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Application
    • 7.4.2 By Type
    • 7.4.3 By End Use
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Application
    • 7.5.2 By Type
    • 7.5.3 By End Use
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Application
    • 7.6.2 By Type
    • 7.6.3 By End Use
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Alcon
    • 9.2.2 Johnson & Johnson Services Inc
    • 9.2.3 Bausch Health Companies Inc
    • 9.2.4 F. Hoffmann-La Roche Ltd
    • 9.2.5 Santen Pharmaceutical Co. Ltd
    • 9.2.6 Novartis AG
    • 9.2.7 Pfizer Inc
    • 9.2.8 Genentech Inc
    • 9.2.9 Carl Zeiss Meditec
    • 9.2.10 Lumenis
    • 9.2.11 Ellex Medical Lasers Ltd
    • 9.2.12 IRIDEX Corp
    • 9.2.13 Topcon Corp
    • 9.2.14 Abbott Medical Optics
    • 9.2.15 Quantel
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제